← Back

Wire · opportunities

Novo's CagriSema delivers about 21% weight loss at lower doses

Published

16 November 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at medwatch.com →

◆ Verified

Fusion42 · 16 November 2026 · Fusion42 review

Novo Nordisk’s Phase 3 trial shows their CagriSema drug achieves about 21% weight loss at doses lower than the 2.4 mg dosage submitted for FDA approval, with a decision expected in 2026.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You must adjust your weight management product roadmaps as lower dose CagriSema shows strong results ahead of FDA approval, setting a new bar for efficacy and dosing strategy.

◆ Coverage

1 source · 16 Nov 2026

◆ Related on Wire

◆ Topics

Healthweight-losspharmaclinical-trialFDA-approvalbiotech